LEXICON PHARMACEUTICALS, INC. (LXRX) Operating Margin
- Operating margin · 12 months: Value -131.43%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -131.43% | Operating income / revenue. Period ending 2026-06-30. $-54.50M ÷ $41.47M × 100 ≈ -131.43% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -54.50M USD | Operating Income (Loss) |
| Revenue | 41.47M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 358.00K USD | Cost of Goods and Services Sold |
| Research and development | 60.27M USD | Research and Development Expense |
| Selling, general and administration | 35.34M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-54.50M | $41.47M | $358.00K | $60.27M | $35.34M | -131.43% |
| 2026-03-31 | $-24.23M | $69.64M | $352.00K | $58.57M | $34.95M | -34.79% |
| 2025-12-31 | $-48.91M | $49.80M | $274.00K | $61.12M | $37.32M | -98.21% |
| 2025-09-30 | $-66.87M | $45.86M | $421.00K | $76.49M | $60.82M | -145.81% |
| 2025-06-30 | $-118.37M | $33.42M | $482.00K | $83.52M | $92.81M | -354.21% |
| 2025-03-31 | $-177.46M | $6.17M | $615.00K | $85.41M | $122.65M | -2876.22% |
| 2024-12-31 | $-197.12M | $6.00M | $616.00K | $84.48M | $143.10M | -3284.74% |
| 2024-09-30 | $-211.12M | $5.12M | $338.00K | $72.56M | $143.45M | -4120.96% |
| 2024-06-30 | $-197.06M | $3.53M | $274.00K | $64.33M | $136.09M | -5583.88% |
| 2024-03-31 | $-185.94M | $2.20M | $116.00K | $61.23M | $126.90M | -8440.35% |
| 2023-12-31 | $-171.75M | $1.11M | $85.00K | $58.89M | $113.98M | -15472.97% |
| 2023-09-30 | $-155.29M | $438.00K | $15.00K | $58.10M | (m) | -35454.57% |
| 2023-06-30 | $-128.75M | $291.00K | $8.00K | $51.10M | (m) | -44245.70% |
| 2023-03-31 | $-108.52M | (m) | (m) | $49.92M | (m) | (m) |
| 2022-12-31 | $-100.76M | $0.00 | $0.00 | $52.82M | (m) | (m) |
| 2022-09-30 | $-95.81M | (m) | (m) | $55.34M | (m) | (m) |
| 2022-06-30 | $-95.68M | (m) | (m) | $60.46M | (m) | (m) |
| 2022-03-31 | $-89.63M | (m) | (m) | $57.36M | (m) | (m) |
| 2021-12-31 | $-87.09M | $0.00 | $0.00 | $55.05M | (m) | (m) |
| 2021-09-30 | $-69.22M | $23.37M | $0.00 | $39.54M | (m) | -296.17% |
| 2021-06-30 | $40.42M | $23.37M | $633.00K | $64.00M | (m) | 172.95% |
| 2021-03-31 | $-6.20M | $23.40M | $1.36M | $111.05M | (m) | -26.50% |
| 2020-12-31 | $-47.80M | $23.40M | $1.93M | $153.62M | (m) | -204.24% |
| 2020-09-30 | $-87.56M | $-256.85M | $2.70M | $193.24M | (m) | 34.09% |
| 2020-06-30 | $50.44M | $29.07M | $2.65M | $179.75M | (m) | 173.55% |
| 2020-03-31 | $96.48M | $29.90M | $3.25M | $135.08M | (m) | 322.66% |
| 2019-12-31 | $141.44M | $32.33M | $3.23M | $91.92M | (m) | 437.49% |
| 2019-09-30 | $176.29M | $289.00M | $3.03M | $63.63M | (m) | 61.00% |
| 2019-06-30 | $-71.31M | $3.65M | $3.00M | $50.73M | (m) | -1955.81% |
| 2019-03-31 | $-83.04M | $9.19M | $2.51M | $64.57M | (m) | -903.55% |
| 2018-12-31 | $-103.28M | $26.58M | $2.49M | $100.24M | (m) | -388.52% |
| 2018-09-30 | $-122.22M | $78.86M | (m) | $135.30M | (m) | -154.98% |
| 2018-06-30 | $-128.70M | $98.95M | (m) | $160.67M | (m) | -130.06% |
| 2018-03-31 | $-132.16M | $97.25M | (m) | $161.01M | (m) | -135.90% |
| 2017-12-31 | $-136.68M | $90.33M | (m) | $156.81M | (m) | -151.30% |
| 2017-09-30 | $-137.23M | $80.33M | (m) | $150.05M | (m) | -170.84% |
| 2017-06-30 | $-142.64M | $81.10M | (m) | $163.45M | (m) | -175.88% |
| 2017-03-31 | $-145.77M | $89.14M | (m) | $184.73M | (m) | -163.54% |
| 2016-12-31 | $-137.16M | $83.34M | (m) | $178.15M | (m) | -164.58% |
| 2016-09-30 | $-17.46M | $187.58M | (m) | $168.19M | (m) | -9.31% |
| 2016-06-30 | $-16.21M | $160.43M | (m) | $138.77M | (m) | -10.10% |
| 2016-03-31 | $-5.88M | $140.72M | (m) | $111.32M | (m) | -4.18% |
| 2015-12-31 | $1.47M | $130.01M | (m) | $95.19M | (m) | 1.13% |
| 2015-09-30 | $-90.34M | $24.22M | (m) | $84.78M | (m) | -373.06% |
| 2015-06-30 | $-97.00M | $24.07M | (m) | $85.77M | (m) | -403.00% |
| 2015-03-31 | $-96.42M | $24.37M | (m) | $86.19M | (m) | -395.67% |
| 2014-12-31 | $-100.37M | $22.85M | (m) | $89.28M | (m) | -439.16% |
| 2014-09-30 | $-113.89M | $2.78M | (m) | $89.51M | (m) | -4094.00% |
| 2014-06-30 | $-104.78M | $2.60M | (m) | $90.80M | (m) | -4028.26% |
| 2014-03-31 | $-107.29M | $2.14M | (m) | $93.31M | (m) | -5015.80% |
| 2013-12-31 | $-102.37M | $2.22M | (m) | $89.68M | (m) | -4607.16% |
| 2013-09-30 | $-109.89M | $1.03M | (m) | $90.41M | (m) | -10668.64% |
| 2013-06-30 | $-107.73M | $1.16M | (m) | $84.20M | (m) | -9255.24% |
| 2013-03-31 | $-104.59M | $1.15M | (m) | $79.86M | (m) | -9102.44% |
| 2012-12-31 | $-108.42M | $1.09M | (m) | $82.57M | (m) | -9955.46% |
| 2012-09-30 | $-117.27M | $1.21M | (m) | $89.69M | (m) | -9659.39% |
| 2012-06-30 | $-113.90M | $1.20M | (m) | $90.15M | (m) | -9515.12% |
| 2012-03-31 | $-114.34M | $1.55M | (m) | $90.94M | (m) | -7362.65% |
| 2011-12-31 | $-114.09M | $1.85M | (m) | $91.83M | (m) | -6170.63% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-95.72M | $4.91M | (m) | $78.52M | (m) | -1950.24% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-89.96M | $10.70M | (m) | $81.24M | (m) | -840.71% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |